EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Clinical efficacy and safety of anti-VEGF biosimilars compared to reference anti-VEGF agents for neovascular age-related macular degeneration: a systematic review, meta-analysis, and meta-regression

Yousef Mesaed Al-Shammari, Yousef M AlDhafiri, Abdullah Kamal Ahmad, Basel Bader Alkharraz, Mohammed Ahmad Al-Awadhi, Rashed Mesaed Alnabhan

International Ophthalmology · 20.03.2026 · 46 (1)

DOI: 10.1007/s10792-026-04043-5 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Ophthalmology, online erschienen am 20.03.2026. Verfasst von Yousef Mesaed Al-Shammari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Al-Bahar Ophthalmology Center, Ibn Sina Hospital, Ministry of Health, Kuwait City, Kuwait. yousef.alnabahan@gmail.com. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Biosimilar Pharmaceuticals, Ranibizumab, Receptors, Vascular Endothelial Growth Factor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Neovascular age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among the elderly. Current treatment options include intravitreal anti-VEGF therapy with ranibizumab and aflibercept. These medications are very effective but expensive. Biosimilars of these expensive intravitreal medications have been proposed as less expensive treatment options. However, their clinical equivalence and safety are of concern. PURPOSE The purpose of this study was to assess the efficacy, safety, and immunogenicity of biosimilars of ranibizumab and aflibercept, and their clinical equivalence with their reference biologics, in the treatment of neovascular AMD. METHODS We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing biosimilar anti-VEGF agents with reference ranibizumab or aflibercept. A comprehensive search of PubMed, Scopus, and Cochrane Library (inception-September 2025) was performed following PRISMA guidelines. Outcomes included change in best-corrected visual acuity (BCVA) at 12 weeks and study endpoint, ≥ 15-letter responder rates, treatment-emergent anti-drug antibodies (ADAs), and ocular/serious ocular adverse events. Risk of bias was assessed using the Cochrane ROB-2 tool. RESULTS Seventeen phase 3 RCTs including 6694 patients were analyzed. Pooled results showed no clinically meaningful differences in BCVA improvement at 12 weeks (MD = - 0.42, p = 0.17) or at study endpoint (MD = - 0.32, p = 0.23) between biosimilars and reference biologics. Responder rates (≥ 15-letter gain) were comparable (RR = 1.06, p = 0.36), as were rates of treatment-emergent ADAs (RR = 0.89, p = 0.40) and ocular adverse events (RR = 0.99, p = 0.86). The subgroup analysis did not demonstrate significant results for biosimilars of aflibercept compared with the reference aflibercept; however, biosimilars of ranibizumab had slightly less BCVA improvement at the end point (RR 0.53, p 0.02). Heterogeneity was low to moderate, and no publication bias was noted. CONCLUSION Our analysis has demonstrated that biosimilars of ranibizumab and aflibercept have equivalent efficacy, safety, and immunogenicity profiles compared with the reference biologics. Future studies should focus on long-term outcomes, switching studies, and health economics to help determine the long-term success of biosimilar therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsBiosimilar PharmaceuticalsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AVisual AcuityHumansIntravitreal InjectionsRandomized Controlled Trials as TopicTreatment OutcomeWet Macular Degeneration

Stichwörter der Autor:innen

BCVAMacularMeta-analysisReviewVEGF

Substanzen

afliberceptAngiogenesis InhibitorsBiosimilar PharmaceuticalsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, Al-Bahar Ophthalmology Center, Ibn Sina Hospital, Ministry of Health, Kuwait City, Kuwait. yousef.alnabahan@gmail.com.
  • Department of Ophthalmology, Jaber Al-Ahmad Hospital, Ministry of Health, Kuwait city, Kuwait.
  • Department of Ophthalmology, Al-Bahar Ophthalmology Center, Ibn Sina Hospital, Ministry of Health, Kuwait City, Kuwait.
  • College of Medicine, University of Alexandria, Alexandria, Egypt.

Zitieren

APA

Al-Shammari, Y. M., AlDhafiri, Y. M., Ahmad, A. K., Alkharraz, B. B., Al-Awadhi, M. A., & Alnabhan, R. M. (2026). Clinical efficacy and safety of anti-VEGF biosimilars compared to reference anti-VEGF agents for neovascular age-related macular degeneration: a systematic review, meta-analysis, and meta-regression. International Ophthalmology, 46(1). https://doi.org/10.1007/s10792-026-04043-5

Vancouver

Al-Shammari YM, AlDhafiri YM, Ahmad AK, Alkharraz BB, Al-Awadhi MA, Alnabhan RM. Clinical efficacy and safety of anti-VEGF biosimilars compared to reference anti-VEGF agents for neovascular age-related macular degeneration: a systematic review, meta-analysis, and meta-regression. International Ophthalmology. 2026;46(1). doi:10.1007/s10792-026-04043-5

BibTeX
@article{AlShammari2026,
  author = {Al-Shammari, Yousef Mesaed and AlDhafiri, Yousef M and Ahmad, Abdullah Kamal and Alkharraz, Basel Bader and Al-Awadhi, Mohammed Ahmad and Alnabhan, Rashed Mesaed},
  title = {Clinical efficacy and safety of anti-VEGF biosimilars compared to reference anti-VEGF agents for neovascular age-related macular degeneration: a systematic review, meta-analysis, and meta-regression},
  journal = {International Ophthalmology},
  year = {2026},
  volume = {46},
  number = {1},
  doi = {10.1007/s10792-026-04043-5}
}
Kostenlos starten →